Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032292 · ClinicalTrials.gov registry record · Phase 1
Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease
A Phase 1 study of Graft Vs Host Disease, sponsored by Facet Biotech.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 7
- Study locations
NCT00032292: Completed Phase 1 study of Graft Vs Host Disease, sponsored by Facet Biotech.
NCT00032292 is a Phase 1 study of Graft Vs Host Disease that has completed, run by Facet Biotech. The registered enrollment target is 34 participants, below the 137-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (75% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00032292, a Phase 1 study of Graft Vs Host Disease, has completed, sponsored by Facet Biotech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this Phase I/II, open-label, dose-escalation study is to evaluate an investigational monoclonal antibody administered as a first-line therapy to patients with acute, Grade II, III, or IV graft-versus-host disease (GVHD). Patients will be eligible for enrollment within 24 hours of beginning standard steroid treatment. The research is being conducted at up to 10 clinical research sites in the US.
Conditions Studied
Interventions
- DRUG Visilizumab
Study Locations (7)
California
- City of Hope National Medical Center - Duarte
- Stanford University Medical Center - Stanford
Missouri
- Washington University School of Medicine - St Louis
North Carolina
- Duke University - Durham
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- MD Anderson Cancer Center - Houston
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2002-03 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
What the finished NCT00032292 record still lists
NCT00032292 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 137-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Graft Vs Host Disease appearing as the primary indexed condition, and to 1 intervention - of which Visilizumab is the first listed.
NCT00032292 lists 7 locations in 6 states (California, Missouri, North Carolina).
Frequently Asked Questions
What is clinical trial NCT00032292 about?
NCT00032292 is a clinical study titled "Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease". The purpose of this Phase I/II, open-label, dose-escalation study is to evaluate an investigational monoclonal antibody administered as a first-line therapy to patients with acute, Grade II, III, or IV graft-versus-host disease (GVHD). Patients will be eligible for enrollment within 24 hours of begi...
What is the current status of trial NCT00032292?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2002-03. Estimated completion is 2006-08.
What conditions does trial NCT00032292 study?
This clinical trial studies the following conditions: Graft Vs Host Disease.
What interventions are being tested in trial NCT00032292?
The interventions under investigation include: Visilizumab (DRUG).
Who is sponsoring clinical trial NCT00032292?
This trial is sponsored by Facet Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00032292 being conducted?
This trial has 7 study locations across California, Missouri, North Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00032292's enrollment target sits among peer trials
34 26th of 36 higher than 11 of 36 other Graft Vs Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graft Vs Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IS-free Treg HaploHCT
RECRUITING · Phase 1
-
A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
RECRUITING · Phase 1
-
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
RECRUITING · Phase 1
-
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
RECRUITING · Phase 1
-
Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
COMPLETED · Phase 1
-
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia